Page last updated: 2024-08-21

fluorobenzenes and Abnormalities, Autosome

fluorobenzenes has been researched along with Abnormalities, Autosome in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Aksoy, H; Berber, AA; Celik, M	1
Ashworth, A; Boyd, J; Brough, R; Edwards, SL; Levine, DA; Lord, CJ; Natrajan, R; Reis-Filho, JS; Vatcheva, R	1

Other Studies

2 other study(ies) available for fluorobenzenes and Abnormalities, Autosome

Article	Year
Genotoxicity evaluation of HMG CoA reductase inhibitor rosuvastatin. Drug and chemical toxicology, 2014, Volume: 37, Issue:3 Topics: Chromosome Aberrations; Comet Assay; DNA Damage; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocytes; Male; Micronucleus Tests; Mitotic Index; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors	2014
Resistance to therapy caused by intragenic deletion in BRCA2. Nature, 2008, Feb-28, Volume: 451, Issue:7182 Topics: Aged; Alleles; Amino Acid Sequence; Base Sequence; BRCA2 Protein; Carboplatin; Cell Line, Tumor; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Fluorobenzenes; Gene Expression Regulation, Neoplastic; Genes, BRCA2; Humans; Middle Aged; Mitomycin; Molecular Sequence Data; Mutation; Open Reading Frames; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Recombination, Genetic; Sequence Deletion	2008

Article

Year

Genotoxicity evaluation of HMG CoA reductase inhibitor rosuvastatin.

Drug and chemical toxicology, 2014, Volume: 37, Issue:3

Topics: Chromosome Aberrations; Comet Assay; DNA Damage; Dose-Response Relationship, Drug; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lymphocytes; Male; Micronucleus Tests; Mitotic Index; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Time Factors

2014

Resistance to therapy caused by intragenic deletion in BRCA2.

Nature, 2008, Feb-28, Volume: 451, Issue:7182

Topics: Aged; Alleles; Amino Acid Sequence; Base Sequence; BRCA2 Protein; Carboplatin; Cell Line, Tumor; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Fluorobenzenes; Gene Expression Regulation, Neoplastic; Genes, BRCA2; Humans; Middle Aged; Mitomycin; Molecular Sequence Data; Mutation; Open Reading Frames; Ovarian Neoplasms; Pancreatic Neoplasms; Phthalazines; Poly(ADP-ribose) Polymerase Inhibitors; Recombination, Genetic; Sequence Deletion

2008